Clinical trial

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

NCT06709859

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-05-01

PhasePHASE2

Study timeline

Study start (actual)2025-05-01Date precision: day

Registry last updated2025-07-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Interventions

Afatinib plus chemotherapy as conversion treatmentDRUG

Sponsors & collaborators

Shandong Public Health Clinical Centerlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06709859 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.